Literature DB >> 22684470

Similar neutralizing activity in the HIV-1 infected long term non-progressors(LTNPs) and typical progressors(TPs).

Zheng Wang1, Tian-yi Li, Jing-yun Li, Li-li Chen, Yong-jian Liu, Han-ping Li, Zuo-yi Bao, Xiao-lin Wang, Dao-min Zhuang, Si-yang Liu, Lin Li.   

Abstract

Neutralizing antibodies are considered to be an important protective parameter used in HIV-1 vaccine evaluation. However, the exact role that neutralizing antibodies plays in controlling the disease progression of HIV-1 infected peoples is still undetermined. In this paper, we compared the protective function of the neutralizing antibody response in the plasma from LTNP and TP against clade B and clade C pseudoviruses. No difference in the neutralizing activities between the plasma from LTNP and TP was found, which was consistent with the most recent reports. In addition, no correlations between the titer or breadth and CD(4+) or viral load in HIV-1 infected individuals were found. The protective roles played by neutralizing antibodies in controlling disease progression of HIV-1 infected people need to be considered in a new viewpoint.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684470      PMCID: PMC8218100          DOI: 10.1007/s12250-012-3239-8

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  9 in total

1.  A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.

Authors:  D Cecilia; C Kleeberger; A Muñoz; J V Giorgi; S Zolla-Pazner
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

Authors:  Zelda Euler; Marit J van Gils; Evelien M Bunnik; Pham Phung; Becky Schweighardt; Terri Wrin; Hanneke Schuitemaker
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.

Authors:  Evelien M Bunnik; Linaida Pisas; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

6.  Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

Authors:  D C Montefiori; G Pantaleo; L M Fink; J T Zhou; J Y Zhou; M Bilska; G D Miralles; A S Fauci
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

7.  Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.

Authors:  P Carotenuto; D Looij; L Keldermans; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

8.  Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".

Authors:  Zheng Wang; Shi-xia Wang; Si-yang Liu; Zuo-yi Bao; Dao-min Zhuang; Lin Li; Chun-hua Zhang; Lu Zhang; Jing-yun Li; Shan Lu
Journal:  Chin Med J (Engl)       Date:  2009-10-05       Impact factor: 2.628

9.  Long-term HIV-1 infection without immunologic progression.

Authors:  S P Buchbinder; M H Katz; N A Hessol; P M O'Malley; S D Holmberg
Journal:  AIDS       Date:  1994-08       Impact factor: 4.177

  9 in total
  2 in total

Review 1.  Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.

Authors:  Kyriakos A Hassapis; Dora C Stylianou; Leondios G Kostrikis
Journal:  Viruses       Date:  2014-12-17       Impact factor: 5.048

2.  The factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis.

Authors:  X C Jia; Z H Xia; N Shi; Y P Wang; Z X Luo; Y L Yang; X Z Shi
Journal:  Epidemiol Infect       Date:  2020-02-24       Impact factor: 2.451

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.